Fosun Pharma Agrees to Covid Vaccine Joint Venture With BioNTech

May 9, 2021, 11:28 AM UTC

A unit of Shanghai Fosun Pharmaceutical Group Co. agreed to establish a joint venture with BioNTech SE for the local production and commercialization of its Covid-19 vaccine.

Shanghai Fosun Pharmaceutical Industry Development will invest as much as $100 million in the partnership including cash, according to a statement to Shanghai Stock Exchange. BioNTech will invest up to $100 million through assets including production technology and a proprietary license.

Under the deal, Fosun Pharmaceutical Industrial will provide a manufacturing facility that has the potential to produce as much as 1 billion doses of the vaccine a year.

To contact Bloomberg News ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.